71 related articles for article (PubMed ID: 15257683)
1. beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis.
Bagnato F; Zivadinov R; Cecchinelli D; Tancredi A; Grop A; Pierallini A; De Lena C; Prencipe M; Reale G; Zorzon M; Millefiorini E
Eur J Neurol; 2004 Jul; 11(7):455-60. PubMed ID: 15257683
[TBL] [Abstract][Full Text] [Related]
2. A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.
Bagnato F; Pozzilli C; Scagnolari C; Bellomi F; Pasqualetti P; Gasperini C; Millefiorini E; Galgani S; Spadaro M; Antonelli G
Neurology; 2002 May; 58(9):1409-11. PubMed ID: 12011292
[TBL] [Abstract][Full Text] [Related]
3. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
5. Beta-2 microglobulin and neopterin as markers of disease activity in multiple sclerosis.
Bagnato F; Durastanti V; Finamore L; Volante G; Millefiorini E
Neurol Sci; 2003 Dec; 24 Suppl 5():S301-4. PubMed ID: 14652795
[TBL] [Abstract][Full Text] [Related]
6. [The effect of cladribine treatment on beta-2 microglobin in the cerebrospinal fluid and serum of patients with multiple sclerosis].
Niezgoda A; Losy J
Neurol Neurochir Pol; 2000; 34(2):281-7. PubMed ID: 10962721
[TBL] [Abstract][Full Text] [Related]
7. Evidence for progressive gray matter loss in patients with relapsing-remitting MS.
Valsasina P; Benedetti B; Rovaris M; Sormani MP; Comi G; Filippi M
Neurology; 2005 Oct; 65(7):1126-8. PubMed ID: 16217074
[TBL] [Abstract][Full Text] [Related]
8. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
9. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Simpson S; Taylor B; Dwyer DE; Taylor J; Blizzard L; Ponsonby AL; Pittas F; Dwyer T; van der Mei I
Mult Scler; 2012 Jun; 18(6):799-806. PubMed ID: 22084489
[TBL] [Abstract][Full Text] [Related]
10. Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study.
Harirchian MH; Tekieh AH; Modabbernia A; Aghamollaii V; Tafakhori A; Ghaffarpour M; Sahraian MA; Naji M; Yazdankhah M
Eur J Neurol; 2012 Feb; 19(2):241-7. PubMed ID: 21771201
[TBL] [Abstract][Full Text] [Related]
11. The beta2-microglobulin/cystatin C ratio--a potential marker of post-transplant lymphoproliferative disease.
Bökenkamp A; Grabensee A; Stoffel-Wagner B; Hasan C; Henne T; Offner G; Lentze MJ
Clin Nephrol; 2002 Dec; 58(6):417-22. PubMed ID: 12508963
[TBL] [Abstract][Full Text] [Related]
12. Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk in acute heart failure patients.
Kawai K; Kawashima S; Miyazaki T; Tajiri E; Mori M; Kitazaki K; Shirotani T; Inatome T; Yamabe H; Hirata K; Yokoyama M
J Cardiol; 2010 Jan; 55(1):99-107. PubMed ID: 20122555
[TBL] [Abstract][Full Text] [Related]
13. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
[TBL] [Abstract][Full Text] [Related]
14. sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis--a cross-sectional pilot study.
Flachenecker P; Jung S; Rieckmann P; Toyka KV
J Neurol; 2002 Aug; 249(8):1001-3. PubMed ID: 12195444
[TBL] [Abstract][Full Text] [Related]
15. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis.
Zivadinov R; Bagnato F; Nasuelli D; Bastianello S; Bratina A; Locatelli L; Watts K; Finamore L; Grop A; Dwyer M; Catalan M; Clemenzi A; Millefiorini E; Bakshi R; Zorzon M
J Neurol Sci; 2004 Aug; 223(2):185-93. PubMed ID: 15337621
[TBL] [Abstract][Full Text] [Related]
16. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.
Sternberg Z; Weinstock-Guttman B; Hojnacki D; Zamboni P; Zivadinov R; Chadha K; Lieberman A; Kazim L; Drake A; Rocco P; Grazioli E; Munschauer F
Mult Scler; 2008 Jul; 14(6):759-63. PubMed ID: 18505774
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
18. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
19. Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis.
Faivre A; Rico A; Zaaraoui W; Crespy L; Reuter F; Wybrecht D; Soulier E; Malikova I; Confort-Gouny S; Cozzone PJ; Pelletier J; Ranjeva JP; Audoin B
Mult Scler; 2012 Sep; 18(9):1251-8. PubMed ID: 22307385
[TBL] [Abstract][Full Text] [Related]
20. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
